Lipid formulations of amphotericin B. Less toxicity but at what economic cost?
Tollemar
J
J
Department of Transplantation Surgery, Huddinge Hospital, Karolinska Institutet, Stockholm, Sweden.
Ringdén
O
O
D000666:Amphotericin B / Q000009:adverse effects / Q000737:chemistry* / Q000191:economics / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects / Q000737:chemistry* / Q000191:economics / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D002986:Clinical Trials as Topic; D003141:Communicable Diseases / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D004337:Drug Carriers / Q000592:standards; D016503:Drug Delivery Systems / Q000592:standards; D004361:Drug Tolerance; D006801:Humans; D008055:Lipids; D008081:Liposomes; D016896:Treatment Outcome
D000935:Antifungal Agents; D004337:Drug Carriers; D008055:Lipids; D008081:Liposomes; D000666:Amphotericin B